Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Open Access
- 14 December 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 7772-7783
Abstract
Aim: To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev).Methods: A total of 286 patients with unresectable HCC treated with Atez/Bev as first‐line systematic therapy were included.Results: Regarding treatment‐related AEs, decreased appetite of any grade, proteinuria of any grade, and fatigue of any grade were found with a frequency of ≥20%. Multivariate analysis adjusted for immune‐related liver injury, immune‐related endocrine dysfunction, proteinuria, fatigue, decreased appetite, hypertension, sex, age, Eastern Cooperative Oncology Group performance status, HCC etiology, HCC stage, Child–Pugh score, and α‐fetoprotein showed that hypertension of any grade (hazard ratio [HR], 0.527; 95% confidence interval [CI], 0.326–0.854;p = 0.009) and α‐fetoprotein ≥100 ng/ml (HR, 1.642; 95% CI, 1.111–2.427;p = 0.013) were independently associated with progression‐free survival. Multivariate analysis adjusted for the same AEs showed that fatigue (HR, 2.354; 95% CI, 1.299–4.510;p = 0.010) was independently associated with overall survival. Median progression‐free survival was 6.5 months (95% CI, 5.2–8.1) in patients without hypertension of any grade and 12.6 months (95% CI, 6.7–not available) in patients with hypertension of any grade (p = 0.035). The overall survival was significantly shorter in patients in whom treatment‐related fatigue of any grade was observed (p < 0.001). Regarding response rates, the disease control rate of patients who developed treatment‐related hypertension (94.2%) was significantly higher than those who did not (79.1%) (p = 0.009).Conclusions: Treatment‐related hypertension is associated with good outcomes in patients with HCC treated with Atez/Bev.Keywords
Funding Information
- Japan Society for the Promotion of Science (KAKENHI 21K07902)
This publication has 40 references indexed in Scilit:
- Mechanism of hypertension and proteinuria during angiogenesis inhibitionJournal Of Hypertension, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasmsCritical Reviews in Oncology/Hematology, 2012
- Bevacizumab-Induced HypertensionBioDrugs, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapyBritish Journal of Cancer, 2011
- Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?The Oncologist, 2010
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 1999